



**ASX Announcement**

**25 July 2025**

## **Atomo Investor Webinar Presentation**

SYDNEY Australia, 25 July 2025 –Atomo Diagnostics Limited (ASX: **AT1**) (**Atomo** or the **Company**) will release its Q4 FY25 Results on Tuesday 29<sup>th</sup> July 2025

A results briefing webinar for analysts and investors, hosted by Managing Director & CEO, John Kelly will be held on Tuesday 29<sup>th</sup> July 2025 at 2pm (AEST).

To access the webinar please pre-register by clicking [this link](#).

Please submit any questions in advance of the webinar commencing to:  
[investorqueries@atomodiagnostics.com](mailto:investorqueries@atomodiagnostics.com)

~ ENDS ~

**For more information, please contact:**

**John Kelly**  
Managing Director & CEO  
e. [john.kelly@atomodiagnostics.com](mailto:john.kelly@atomodiagnostics.com)  
p. +61 401 922 279

**Investor Queries**  
[investorqueries@atomodiagnostics.com](mailto:investorqueries@atomodiagnostics.com)

*This announcement was authorised by the Managing Director & CEO on behalf of the Board.*

### **About Atomo**

Atomo is an Australian-headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.

Atomo's unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including COVID-19, HIV, viral vs bacterial differentiation and female health. See more at [www.atomodiagnostics.com](http://www.atomodiagnostics.com)